What is the sensitivity of coronary computed tomography angiography (CTA) for detecting clinically significant coronary artery stenosis in adults being evaluated for suspected coronary artery disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sensitivity of Coronary CTA

Coronary CTA demonstrates a sensitivity of 93-98% for detecting clinically significant coronary artery stenosis (≥50% diameter stenosis) in adults with suspected coronary artery disease.

Diagnostic Performance

The most recent and comprehensive guideline data from the 2019 ESC guidelines 1 provides definitive performance metrics:

  • For obstructive CAD (≥50% stenosis): Sensitivity 93% (89-96%)
  • For functionally significant CAD: Sensitivity 93% (89-96%)
  • Negative likelihood ratio: 0.13 (0.06-0.25), indicating excellent ability to rule out disease

These values are corroborated by the 2022 ACR Appropriateness Criteria 2, which reports 95% sensitivity in the CCTA ACCURACY trial and 97% sensitivity in the VERDICT trial 3 specifically for patients with acute coronary syndrome.

Performance Characteristics by Clinical Context

Standard Populations

The 2017 ACR guidelines 4 report sensitivity of 91% with a negative predictive value of 83% across general populations. The negative predictive value consistently exceeds 90% across multiple studies 1, 2, 3, making coronary CTA particularly valuable for ruling out significant stenosis.

High-Risk Populations

In the VERDICT trial 3 of patients with confirmed non-ST-elevation acute coronary syndrome—representing a high-risk cohort—coronary CTA maintained:

  • Sensitivity: 96.5% (94.9-97.8%)
  • Negative predictive value: 90.9% (86.8-94.1%)

This demonstrates that sensitivity remains excellent even in populations with high disease prevalence.

Critical Limitations That Reduce Sensitivity

Several factors can cause false-negative results and must be recognized:

Technical Factors

  • Extensive coronary calcification: Creates blooming artifacts that obscure vessel lumen 1
  • Irregular heart rate or arrhythmias: Motion artifacts can mask stenoses 4
  • Severe obesity: Degrades image quality 1
  • Poor breath-holding: Results in motion blur

Anatomical Factors

  • Small vessel size (<1.5mm): Below resolution limits 4
  • Previous stenting: Metal artifacts impair visualization 1
  • Bypass grafts: Incomplete evaluation of native vessels 1

The 2019 ESC guidelines 1 explicitly state that coronary CTA is not recommended when these conditions make good image quality unlikely, as sensitivity drops substantially in these scenarios.

Comparison to Other Modalities

When compared to functional testing 1:

  • PET: 89-90% sensitivity
  • Stress CMR: 89-90% sensitivity
  • SPECT: 73% sensitivity
  • Coronary CTA: 93% sensitivity

Coronary CTA demonstrates the highest sensitivity among non-invasive modalities for detecting anatomic stenosis, though it should be noted that high sensitivity comes at the cost of lower specificity (53% for functionally significant disease) 1.

Clinical Implications

The 2024 ESC guidelines 5 and 2021 AHA/ACC guidelines 6 both recommend coronary CTA as a first-line test in patients with low-to-moderate pre-test probability specifically because of its high sensitivity and negative predictive value. A negative coronary CTA effectively rules out obstructive CAD with >95% certainty in appropriate patients 1, 5.

However, stenoses of 50-90% detected on CTA require functional testing for confirmation 1, as anatomic severity does not always correlate with hemodynamic significance. The high sensitivity for anatomic disease does not translate to equivalent sensitivity for ischemia-causing lesions.

Key Pitfall to Avoid

Do not order coronary CTA in patients with extensive calcification (Agatston score >400), irregular rhythms, or severe obesity expecting the same 93-98% sensitivity—these conditions substantially degrade performance and lead to non-diagnostic studies 1. In such patients, functional testing (PET, stress CMR) should be the initial approach 5.

Related Questions

What are the 2026 American Diabetes Association (ADA) clinical practice recommendations for screening, diagnosis, glycemic targets, lifestyle modification, pharmacologic therapy, cardiovascular and renal risk reduction, and monitoring in adults with diabetes?
What management plan, including lifestyle modifications, laboratory testing, medication regimen, and follow‑up schedule, should be used to safely reduce the blood pressure of a 26‑year‑old active‑duty male with obesity (body mass index [BMI] 36), prediabetes, dyslipidemia, and an average blood pressure of 144/87 mm Hg to below 130/90 mm Hg within one month for military operational clearance?
In a 26‑year‑old African‑American man with obesity (BMI 36), pre‑diabetes (HbA1c ≈ 5.8‑5.9 %), mixed dyslipidemia, and stage 1 hypertension (average blood pressure 144/87 mm Hg), what non‑pharmacologic measures, single‑agent pharmacologic options, laboratory tests, and follow‑up schedule are recommended to safely lower his blood pressure to below 130/90 mm Hg within one month?
What discharge plan should be recommended for a postpartum woman, two days after delivery, with type 2 diabetes on insulin glargine (Lantus) 9 U daily without carbohydrate coverage, who is breastfeeding and currently has hyperglycemia?
What is 0.37 mmol/L of glucose expressed in mg/dL?
What is the recommended management for a child with suspected PANDAS presenting with neuropsychiatric symptoms?
Can oral minoxidil induce hyperkalemia?
After initiating statin therapy, what changes in the lipid profile (LDL‑cholesterol, total cholesterol, triglycerides, HDL‑cholesterol) are expected for an adequate therapeutic effect?
Can hyoscine (scopolamine) cause chest pain as an adverse effect?
What is the appropriate treatment for spontaneous epistaxis in an adolescent?
Can a healthy 9-year-old child safely receive acetaminophen (Tylenol) and an over‑the‑counter cough suppressant containing dextromethorphan at the same time?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.